Sunil Ramrakhiani, MD
Gastroenterology · Fort Wayne, INNPI 1407805849
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 510 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 60.1% of it on its own, with 27 other manufacturers making up the rest.
Across 510 payments — averaging $13.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Takeda Pharmaceuticals U.S.A., Inc.$467
- Nestle Healthcare Nutrition Inc.$335
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$300
- Lilly USA, LLC$191
- Sanofi$190
- plus $1K from 22 others
Across 2 payments — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Olympus Corporation Of The Americas$4K
What the payments were for
- Food & beverage$6,886100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 351 | $4,137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $467 |
| Nestle Healthcare Nutrition Inc. | 36 | $335 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $300 |
| Lilly USA, LLC | 8 | $191 |
| Sanofi | 8 | $190 |
| Medtronic | 2 | $158 |
| Merck | 8 | $134 |
| Gilead | 8 | $111 |
| Intercept Pharmaceuticals, Inc. | 6 | $95 |
| Johnson & Johnson | 6 | $81 |
| Pfizer | 5 | $75 |
| E.r. Squibb & Sons, L.L.C. | 1 | $70 |
| Bristol Myers Squibb | 5 | $68 |
| Regeneron Healthcare Solutions, Inc. | 2 | $63 |
| Aimmune Therapeutics, Inc. | 3 | $58 |
| QOL Medical, LLC | 3 | $56 |
| Romark Laboratories, LC | 3 | $49 |
| Vivus LLC | 3 | $47 |
| Ironwood Pharmaceuticals, Inc | 3 | $43 |
| Braintree Laboratories, Inc. | 2 | $28 |
| Madrigal Pharmaceuticals | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Olympus America Inc. | 1 | $17 |
| Redhill Biopharma Inc. | 1 | $17 |
| Sandoz | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Echosens North America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GI Genius$138
How this compares
$6,886 in reported general payments places this provider in the 75th percentile of 323 gastroenterology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 12 | $114,720 |
| Humira(Cf) PenAdalimumab | 14 | $99,617 |
| CreonLipase/Protease/Amylase | 17 | $79,414 |
| LinzessLinaclotide | 18 | $14,798 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 496 | $7,091 |
| Ursodiol | 26 | $4,531 |
| Pantoprazole Sodium | 330 | $3,014 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 161 | $2,207 |
| Omeprazole | 63 | $1,520 |
| Famotidine | 110 | $1,415 |
| Sucralfate | 45 | $1,263 |
| Ondansetron OdtOndansetron | 15 | $465 |
| Dicyclomine Hcl | 16 | $234 |
| Spironolactone | 17 | $171 |
| Furosemide | 15 | $33 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $95 | $114,72012 claims |
| AbbVieCreon, Linzess | $4,137 | $94,21235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 323 gastroenterology providers in Indiana.
Other gastroenterology in Fort Wayne
- Efesomwan AisienFort Wayne$86K
- Melissa GarrettFort Wayne$59K
- Abdo SaadFort Wayne$45K
- Mariajose Rojas de LeonFort Wayne$40K
- Sushil JainFort Wayne$12K
- Sepideh Farzin MoghadamFort Wayne$12K
- Andrew KatzFort Wayne$12K
- Douglas RexIndianapolis$557K
- Ajay JainIndianapolis$432K
- Jonathan ObertNew Albany$302K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.